Next Generation Antibody Therapeutics Market (2nd Edition): Industry Trends and Global Forecasts, Till 2035 - Distribution by Drug, Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, Key Geographical Regions and Leading P

Next Generation Antibody Therapeutics Market

As per Roots Analysis, the next generation antibody therapeutics market is estimated to grow

from USD 843 million in the current year to USD 2,161 million by 2035, at a CAGR of 9.87%

during the forecast period, till 2035.

Next Generation Antibody Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Drugs

• Adcetris
• Kadcyla
• ELZONRIS
• Besponsa
• LYMPHIR
• Fibromun
• Nidlegy
• Iomab-B
• TLX 591

Type of Novel Antibody

• Radioisotope Immunoconjugates
• Immunocytokines
• Immunotoxins

Target Indication

• Previously Untreated Systemic Anaplastic Large Cell Lymphoma (SALCL) or other CD30-expressing Peripheral T-cell Lymphomas (PTCL)
• Classical Hodgkin Lymphoma
• Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or
• CD30-expressing Mycosis Fungoides (MF)
• Diffuse Large B-cell Lymphoma
• Relapsed or Refractory B-cell precursor Acute
• Lymphoblastic Leukemia
• HER2-positive breast cancer
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Locally Advanced, Melanoma / Stage III B / C Melanoma
• Relapsed or Refractory Cutaneous T-cell Lymphoma
• Relapsed / Refractory Acute Myeloid
• Leukemia
• Metastatic Castration-resistant Prostate Cancer
• Soft Tissue Sarcoma

Type of Therapy

• Combination Therapy
• Monotherapy

Route of Administration

• Intratumoral
• Intravenous

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa

Novel Antibody Therapies Market: Growth and Trends

Antibodies, or immunoglobulins, are proteins generated by the immune system that identify and attach to particular antigen markers on cells or tissues, acting as the primary defense against various ailments. Utilizing the accuracy of antibody-antigen interactions, innovative antibody treatments have shown considerable promise in enhancing patient results. In recent years, numerous innovative antibody treatments received approval from the USFDA, signifying notable progress in the treatment of a range of illnesses, such as metabolic disorders, cardiovascular issues, cancer, and rare diseases. These authorizations demonstrate the effectiveness of biotechnological methods in tackling significant healthcare issues and underscore the role of antibody therapies in contemporary medicine. Increased funding and investments, along with partnership initiatives, are vital for the research and development of new antibodies targeting various disorders. Moreover, numerous advanced technologies are transforming the identification and development of new therapies, fundamentally changing treatment approaches.
 
Novel Antibody Therapies Market: Key Insights

The report delves into the current state of the global novel antibody therapies market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over 70 radioisotope immunoconjugates are approved / being investigated across different stages of development for the treatment of various diseases; of these, >80% of the therapies are in early-stages of development.
• Close to 70% of the monotherapies can be administered intravenously; of these, majority (96%) of the therapies are under clinical stages of development.
• Over 35 immunocytokines are currently approved / being investigated across various stages of development for the treatment of various diseases; of these, nearly 60% of the therapies are in early-stages of development.
• Presently, over 45% of immunocytokines in early stages of development are in conjugation with IL-2 and IL-15 types of cytokine; of these, majority (80%) of the therapies can be administered as combination therapy.
• Nearly 60 immunotoxins are currently approved / being investigated across different stages of development for the treatment of various diseases; of these, more than 45% of the therapies are in early-stages of development.
• Presently, nearly 80% of the late-stage immunotoxins (phase II and phase II / III) are administered via injections; further, 56% immunotoxins are in conjugation with microbial toxins.
• Most of the trials were registered in 2024; notably, a significant proportion (72%) of the total trials are currently recruiting patients for the investigation of novel antibody therapies.
• The growing scientific literature highlights the active involvement of stakeholders in the research and development of novel antibody therapies; close to 35% of the articles were published in the previous year.
• Majority of the patent assignees are non-industry players; however, over the past few years, the contribution of industry players in the patent filing activity has also increased.
• Close to 20% deals inked in this domain are supply agreements; of these, 44% agreements were signed in 2022 in order to address the growing demand for novel antibodies.
• Using our proprietary forecast model, we estimated the current size of the global novel antibody therapies market, taking into consideration the historical trends, data and inputs obtained from exhaustive research.
• Currently, the global novel antibody therapies market is dominated by drugs that are intended to target HER2-positive breast cancer, followed by classical Hodgkin lymphoma.

Novel Antibody Therapies Market: Key Segments

Adcetris Drug Captures the Largest Share in the Next Generation Antibody Therapeutics Market

Currently, Adcetris holds the higher market share of close to 45% due to its early approvals and proven effectiveness in hematologic cancers. LYMPHIR is expected to expand at an increased CAGR of 18% throughout the forecast period.

Immunotoxins Segment Holds the Majority of the Next Generation Antibody Therapeutics Market Share

The higher share of immunotoxins segment in the current year can be attributed to their superior targeted cytotoxicity and effectiveness against resistant cancer cells, as per next generation antibody therapeutics market forecast. Further, the immunocytokines sector is expected to exhibit the greatest growth potential, of over 40%, throughout the forecast period.

HER2-PBC Hold the Largest Share in the Next Generation Antibody Therapeutics Market

In the present year, HER2-PB captures a significant market share of nearly 45% in novel antibody therapies, driven by the growing incidence of HER2-positive breast cancer and the heightened use of targeted treatments that lead to substantial enhancements in patient outcomes and survival rates. The segment for relapsed or refractory cutaneous T-cell lymphoma is expected to exhibit the greatest growth potential of nearly 20% throughout the forecast period.

Monotherapy Dominates Next Generation Antibody Therapies Industry

Monotherapy segment holds most of the market share in the current year owing to its ability to provide highly specific targeting with fewer side effects. The combination therapy segment is likely to show the highest growth potential of close to 45%, during the forecast period.

Intravenous Route of Administration Dominates Next Generation Antibody Therapeutics Market Share

Currently, intravenous route of administration, the intravenous method dominates the market due to its capacity to provide a quick onset of action and improved bioavailability needed for effectively delivering large antibodies. The intratumoral method of delivery is expected to expand at a higher CAGR, fueled by its capacity to attain greater local drug levels, reduce systemic toxicity, and enhance treatment effectiveness

North America is Likely to Propel in the Next Generation Antibody Therapeutics Market in the Coming Years

According to our next generation antibody therapeutics market report, North America is likely to capture the majority (64%) of the market share in the current year, and this trend is unlikely to change in the future. This can be attributed to the strong healthcare system, innovative platforms for developing new antibody treatments, and a significant emphasis on personalized care, positioning this region at the forefront of novel antibody treatments.

Example Players in the Next Generation Antibody Therapeutics Market

• Actinium Pharmaceuticals
• Pfizer
• Philogen
• Roche
• Telix Pharmaceuticals
• Y-mAbs Therapies

Novel Antibody Therapies Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the novel antibody therapies market, focusing on key market segments, including [A] drug, [B] type of novel antibody, [C] target indication, [D] type of therapy, [E] route of administration and [F] leading players.
• Market Landscape 1: A detailed assessment of the current market landscape of radioisotope immunoconjugates, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of therapy, [C] route of administration, [D] dosing frequency, [E] type of radioisotope, [F] mode of administration, [G] mechanism of action [H] therapeutic area, [I] year of establishment, [J] company size, [K] location of headquarters, [L] type of developer and [M] most active players.
• Market Landscape 2: A detailed assessment of the current market landscape of immunocytokines, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of cytokine, [C] type of therapy, [D] dosing frequency, [E] mechanism of action, [F] mode of administration, [G] type of antigen / format, [H] route of administration [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Market Landscape 3: A detailed assessment of the current market landscape of immunotoxins, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of toxin, [C] dosing frequency, [D] type of therapy, [E] mode of administration, [F] type of target, [G] mechanism of action, [H] route of administration, [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the engaged in the development of novel antibody therapies. Each profile features [A] a brief overview of the company, [B] its financial information, [C] details on its drug portfolio, [D] recent developments and an [E] informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating different novel antibody therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] study design, patient gender, [F] type of sponsor / collaborator, [G] most active industry and [H] geographical distribution.
• Publication Analysis: A detailed review of various peer-reviewed, scientific articles related to research on novel antibody therapies, based on relevant parameters, such as [A] year of publication, [B] type of publication, [C] popular publisher and [D] key journal.
• Patent Analysis: in-depth analysis of various patents that have been filed / granted for novel antibody therapies, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] type of applicant, [D] application year, [E] patent jurisdiction, patent age, [F] CPC symbols, [G] leading players.
• Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
• Big Pharma Players: An analysis of big pharma players engaged in the field of novel antibody therapies, based on several relevant parameters, such as [A] developer strength, [B] portfolio strength, and [C] portfolio diversity.
• Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What is the current global capacity of developers?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Show more